Oncimmune is not the only company looking to use the immune system to diagnose cancer. But its growth plans are intense, and it intends to prove the economic benefits of…
A study of a liquid biopsy and another looking at tumour mutational burden testing give early indications of Foundation’s approval strategy.
With one cancer blood test established on the market Guardant is starting down the road to validating another – this time as a screening assay.
Guardant gets a liquid biopsy trial win, but if it wants to drive sales it must get cancer societies on board.
The J&J-Auris tie-up will yield a huge return for investors who went in big.
The value of listings hit a new quarterly high courtesy of Guardant and Axonics.
Full results of the Mystic study present a controversial path forward for Imfinzi, and set the stage for the upcoming Neptune trial to be overhauled.
Guardant Health says its tests have a market opportunity of $35bn, and now has to justify investors’ faith.
In a truly extraordinary year, the top 10 venture rounds made up more than half of the total invested.